{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Joshi YB"],"funding":["RRD VA","NIMH NIH HHS"],"pagination":["838-847"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8440496"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["178(9)"],"pubmed_abstract":["<h4>Objective</h4>Many psychotropic medications used to treat schizophrenia have significant anticholinergic properties, which are linked to cognitive impairment and dementia risk in healthy subjects. Clarifying the impact of cognitive impairment attributable to anticholinergic medication burden may help optimize cognitive outcomes in schizophrenia. The aim of this study was to comprehensively characterize how this burden affects functioning across multiple cognitive domains in schizophrenia outpatients.<h4>Methods</h4>Cross-sectional data were analyzed using inferential statistics and exploratory structural equation modeling to determine the relationship between anticholinergic medication burden and cognition. Patients with a diagnosis of schizophrenia or schizoaffective disorder (N=1,120"],"journal":["The American journal of psychiatry"],"pubmed_title":["Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia."],"pmcid":["PMC8440496"],"funding_grant_id":["R01 MH119219","R01 MH079777","R33 MH123603","IK2 RX003395","R01 MH065558","R01 MH065707","R01 MH042228","R33 MH125114","R01 MH065571","K23 MH102420","R01 MH065578","R01 MH065554","R25 MH101072"],"pubmed_authors":["Gur RC","MacDonald LR","Sugar CA","Gur RE","Sprock J","Green MF","Silverman JM","Nuechterlein KH","Radant AD","Lazzeroni LC","Joshi YB","Stone WS","Greenwood TA","Molina JL","Turetsky BI","Braff DL","Thomas ML","Tsuang DW","Tsuang MT","Nungaray JA","Light GA","Swerdlow NR"],"additional_accession":[]},"is_claimable":false,"name":"Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.","description":"<h4>Objective</h4>Many psychotropic medications used to treat schizophrenia have significant anticholinergic properties, which are linked to cognitive impairment and dementia risk in healthy subjects. Clarifying the impact of cognitive impairment attributable to anticholinergic medication burden may help optimize cognitive outcomes in schizophrenia. The aim of this study was to comprehensively characterize how this burden affects functioning across multiple cognitive domains in schizophrenia outpatients.<h4>Methods</h4>Cross-sectional data were analyzed using inferential statistics and exploratory structural equation modeling to determine the relationship between anticholinergic medication burden and cognition. Patients with a diagnosis of schizophrenia or schizoaffective disorder (N=1,120","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-04T09:37:18.04Z","creation":"2025-04-04T09:37:18.04Z"},"accession":"S-EPMC8440496","cross_references":{"pubmed":["33985348"],"doi":["10.1176/appi.ajp.2020.20081212"]}}